Jupiter Neurosciences (JUNS) said Thursday that it has entered into a partnership with Zina Biopharmaceuticals for an upcoming phase 2a clinical trial to evaluate Jupiter's Jotrol resveratrol-based platform in Parkinson's disease.
Zina will assist with trial design, regulatory strategy, and trial site selection, according to Jupiter.
The study has a primary objective of evaluating the safety and tolerability of Jotrol, with secondary endpoints to assess the drug's pharmacokinetics and pharmacodynamics, Jupiter said.
Jupiter also said it is exploring partnerships to look into Jotrol's potential for treating other neuroinflammatory and metabolic disorders, including Alzheimer's disease.
Shares of Jupiter were down more than 5% in recent trading.
Price: 1.15, Change: -0.07, Percent Change: -5.74
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。